Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
Current SymbolNYSE:DPLO
Previous Symbol
CUSIPN/A
Phone888-720-4450
Debt
Debt-to-Equity Ratio0.58
Current Ratio0.95
Quick Ratio0.66
Price-To-Earnings
Trailing P/E Ratio18.57
Forward P/E Ratio19.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 billion
Price / Sales0.26
Cash Flow$1.8396 per share
Price / Cash Flow8.48
Book Value$10.88 per share
Price / Book1.43
Profitability
EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.04%
Return on Equity5.31%
Return on Assets2.17%
Miscellaneous
Employees2,419
Outstanding Shares74,470,000
Market Cap$1.16 billion
OptionableOptionable
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy Inc (NYSE:DPLO) released its earnings results on Tuesday, November, 6th. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.21. The business earned $1.37 billion during the quarter, compared to the consensus estimate of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The firm's revenue for the quarter was up 22.0% on a year-over-year basis. During the same period last year, the business posted $0.01 EPS. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What guidance has Diplomat Pharmacy issued on next quarter's earnings?
Diplomat Pharmacy updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $(0.10)-$0.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.83. The company issued revenue guidance of $5.5-5.7 billion, compared to the consensus revenue estimate of $5.64 billion.
What price target have analysts set for DPLO?
11 equities research analysts have issued 1-year target prices for Diplomat Pharmacy's shares. Their predictions range from $15.00 to $35.00. On average, they expect Diplomat Pharmacy's share price to reach $24.70 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.
What is the consensus analysts' recommendation for Diplomat Pharmacy?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diplomat Pharmacy.
Has Diplomat Pharmacy been receiving favorable news coverage?
Media headlines about DPLO stock have trended positive on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Diplomat Pharmacy's key competitors?
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Joel Saban, Pres (Age 50)
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
- Mr. Atul Kavthekar, CFO & Treasurer
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
- Mr. Brian Thomas Griffin, CEO & Chairman (Age 59)
Who are Diplomat Pharmacy's major shareholders?
Diplomat Pharmacy's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.38%), Janus Henderson Group PLC (7.92%), Vanguard Group Inc. (7.33%), Capital World Investors (7.11%), Capital International Investors (6.86%) and Frontier Capital Management Co. LLC (4.75%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.
Which institutional investors are selling Diplomat Pharmacy stock?
DPLO stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Broadview Advisors LLC, TIAA CREF Investment Management LLC, Engineers Gate Manager LP, Credit Suisse AG, Teachers Advisors LLC and Blair William & Co. IL. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.
Which institutional investors are buying Diplomat Pharmacy stock?
DPLO stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Frontier Capital Management Co. LLC, BlackRock Inc., Matarin Capital Management LLC, Commerce Bank, Dimensional Fund Advisors LP, Janus Henderson Group PLC and Man Group plc. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $15.60.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $1.16 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
What is Diplomat Pharmacy's official website?
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
